IP Verse

Melflufen Dosage Regimens For Cancer - EP3383385

The patent EP3383385 was granted to Oncopeptides on Sep 6, 2023. The application was originally filed on Dec 1, 2016 under application number EP16805792A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP3383385

ONCOPEPTIDES
Application Number
EP16805792A
Filing Date
Dec 1, 2016
Status
Patent Maintained As Amended
Aug 4, 2023
Grant Date
Sep 6, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

LUIGIApr 29, 2021TER MEER STEINMEISTER & PARTNERADMISSIBLE
SYNTHONApr 28, 2021HOFFMANN EITLEADMISSIBLE

Patent Citations (3) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
INTERNATIONAL-SEARCH-REPORTUS2014302014
INTERNATIONAL-SEARCH-REPORTWO2014065751
OPPOSITIONWO2014065751

Non-Patent Literature (NPL) Citations (16) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
INTERNATIONAL-SEARCH-REPORT- C PABA-PRADA, "Determination of the MTD and Encouraging Results in an Ongoing Open-Label Phase 1/2a Study of the Safety and Efficacy of Melflufen and Dexamethasone in Combination for Patients with Relapsed and Relapsed-Refractory Multiple Myeloma (RRMM) | Blood Journal", BLOOD, (20141204), vol. 124, no. 21, page 2123, XP055337105 [Y] 1-27 * the whole document *-
INTERNATIONAL-SEARCH-REPORT- MAGAROTTO V ET AL, "ENCOURAGING PRELIMINARY DATA IN ONGOING OPEN-LABEL PHASE 1/2 STUDY OF SAFETY AND EFFICACY OF MELFLUFEN AND *DEXAMETHASONE FOR PATIENTS WITH RELAPSED AND RELAPSED-REFRACTORY MULTIPLE MYELOMA", HAEMATOLOGICA, THE HEMATOLOGY JOURNAL : OFFICIAL ORGAN OF THE EUROPEAN HEMATOLOGY ASSOCIATION, FONDAZIONE FERRATA STORTI, IT, (20150601), vol. 100, no. Suppl.1, ISSN 0390-6078, page 89, XP009193143 [Y] 1-25,27 * the whole document *-
INTERNATIONAL-SEARCH-REPORT- VOORHEES PETER M ET AL, "Efficacy of Melflufen, a Peptidase Targeted Therapy, and Dexamethasone in an Ongoing Open-Label Phase 2a Study in Patients with Relapsed and Relapsed Refractory Multiple Myeloma (RRMM) Including an Initial Report on Progression Free Survival", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, (20151201), vol. 126, no. 23, ISSN 0006-4971, XP009193142 [AP] 1-25 * the whole document *-
INTERNATIONAL-SEARCH-REPORT- BERGLUND ÅKE ET AL, "First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies", INVESTIGATIONAL NEW DRUGS, MARTINUS NIJHOFF PUBLISHERS, BOSTON, US, vol. 33, no. 6, doi:10.1007/S10637-015-0299-2, ISSN 0167-6997, (20151110), pages 1232 - 1241, (20151110), XP035906340 [Y] 1-25 * page 1233, column 2, paragraph 4 * * page 1236, paragraph 1; figure 1 * * page 1240, column 1, paragraph 2 * * page 1240, paragraphs 3,4 *
INTERNATIONAL-SEARCH-REPORT- RAY ARGHYA ET AL, "A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells", BRITISH JOURNAL OF HAEMATOLOGY, (201608), vol. 174, no. 3, pages 397 - 409, XP055356365 [YP] 27 * page 398, column 1, lines 5-22, paragraph 1 *
INTERNATIONAL-SEARCH-REPORT- D. CHAUHAN ET AL, "In Vitro and In Vivo Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, against Multiple Myeloma Cells", CLINICAL CANCER RESEARCH, US, (20130412), vol. 19, no. 11, doi:10.1158/1078-0432.CCR-12-3752, ISSN 1078-0432, pages 3019 - 3031, XP055288158 [Y] 1-27 * the whole document *
OPPOSITION- Anonymous, "An Open-Label Phase I/IIa Study of the Safety and Efficacy of Melphalan-flufenamide (Melflufen) and Dexamethasone Combination for Patients With Relapsed and/or Relapsed-Refractory Multiple Myeloma NCT01897714", ClinicalTrials.gov, (20130712), pages 1 - 12, ClinicalTrials.gov, URL: https://clinicaltrials.gov/ct2/show/NCT01897714, (20210510), XP055803114-
OPPOSITION- Anonymous, "Clinical Trials: What You Need to Know", American Cancer Society, (20200101), pages 1 - 29, American Cancer Society, URL: https://www.cancer.org/content/dam/CRC/PDF/Public/6800.00.pdf, (20210510), XP055803122-
OPPOSITION- Anonymous, "Melphalan Injection: MedlinePlus Drug Information", MedlinePlus, (20210408), pages 1 - 5, MedlinePlus, URL: https://medlineplus.gov/druginfo/meds/a612019.html, (20210514), XP055804388-
OPPOSITION- MAGAROTTO et al., "Encouraging preliminary data in ongoing open-label phase 1/2 study of safety and efficacy of melflufen and dexamethasone for patients with relapsed and relapsed-refractory multiple myeloma", haematologica, (20150611), vol. 100, no. sl, page 89, XP009193143-
OPPOSITION- Magarotto V; et al, "ENCOURAGING PRELIMINARY DATA IN ONGOING OPEN-LABEL PHASE 1/2 STUDY OF SAFETY AND EFFICACY OF MELFLUFEN AND *DEXAMETHASONE FOR PATIENTS WITH RELAPSED AND RELAPSED-REFRACTORY MULTIPLE MYELOMA", Haematologica, Fondazione Ferrata Storti, IT, IT, (20150601), vol. 100, no. Suppl.1, ISSN 0390-6078, page 89, XP009193143-
OPPOSITION- Mellqvist, Et Al, "An ongoing open-label phase 1/2a study of safety and efficacy of melflufen and dexamethasone for patients with relapsed and relapsed-refractory multiple myeloma (RRMM", Haematologica, (20140101), vol. 99, no. 1, pages 375 - .376, XP055803103-
OPPOSITION- Mellqvist, Et Al, "An ongoing open-label phase 1/2a study of safety and efficacy of melflufen and dexamethasone for patients with relapsed and relapsed-refractory multiple myeloma (RRMM", RRMM, (20140615), vol. 99, no. 1, pages 1 - 13, XP055803096-
OPPOSITION- PABA-PRADA et al., "Determination of the MTD and Encouraging Results in an Ongoing Open-Label Phase 1/2a Study of the Safety and Efficacy of Melflufen and Dexamethasone in Combination for Patients with Relapsed and Relapsed-Refractory Multiple Myeloma (RRMM", Blood, (20140000), vol. 124, no. 21, page 2123, XP055337105-
OPPOSITION- BERGLUND AKE et al., "First-in-human, phase ////0 clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies", Investigational New Drugs, (20150000), vol. 33, no. 6, doi:10.1007/s10637-015-0299-2, pages 1232 - 1241, XP035906340
OPPOSITION- D. CHAUHAN et al., "In Vitro and In Vivo Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, against Multiple Myeloma Cells", Clinical Cancer Research, (20130000), vol. 19, no. 11, doi:10.1158/1078-0432.CCR-12-3752, pages 3019 - 3031, XP055288158

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents